Antiflu-Des (Amantadine Hydrochloride, Chlorphenamine Maleate, Paracetamol)

Active Ingredient: Amantadine Hydrochloride, Chlorphenamine Maleate, Paracetamol
Dosage: 50 mg/3 mg/300 mg
Route of Administration: Oral
Dosage Form: Capsules
Quantity per package: 24 capsules per pack

Why is Antiflu-Des not sold in the USA?

Antiflu-Des is not used in the USA mainly because the individual components are available but are recommended in different contexts. Amantadine, for instance, is no longer recommended for treating or preventing influenza in the United States due to widespread resistance. The U.S. health authorities typically recommend vaccines and other antiviral drugs that are considered more effective and have a broader spectrum of action against different flu viruses.

Alternative Antiflu-Des Drugs Sold in the USA

Here are similar drugs available in the USA that are used for the treatment of influenza and its symptoms. These are grouped based on their primary action:

What is Antiflu-Des?

Antiflu-Des is indicated in the treatment of influenza. The drug acts against the virus that causes it and relieves the accompanying symptoms such as fever, muscle pain and runny nose. Amantadine Hydrochloride acts as an antiviral that specifically targets influenza A virus, helping to inhibit its replication. Chlorphenamine Maleate is an antihistamine that helps alleviate symptoms like runny nose and watery eyes, while Paracetamol is effective for reducing fever and alleviating pain associated with the flu.

Indications

The drug is indicated in the treatment of influenza by influenza virus of group A, including subtypes H3N2, H2N2 and H1N1 since it has specific antiviral, analgesic, antipyretic, decongestant and antihistamine action.

Dosage and administration

Adults and over 12 years: 1 capsule every 8 hours. To obtain greater therapeutic efficacy, it is recommended to start treatment within the first 48 hours after the onset of symptoms.

Contraindications

Antiflu-Des should not be given to elderly people or people who have a history of psychic disorders or seizures, patients with liver, kidney disorders, hyperthyroidism and uncontrolled hypertension, epilepsy, glaucoma, myasthenia gravis, prostatic hypertrophy, patients under treatment with MAO inhibitors or cerebral arteriosclerosis.

Side effects

The administration of this medicine may cause nausea, vomiting, epigastric pain, jaundice, leukopenia, anemia or liver damage, insomnia, headache, dizziness, disorientation, mental confusion and hallucinations, drowsiness, sedation, asthenia, blurred vision and ataxia, anorexia, dry mouth, epigastric burning, constipation or diarrhea, tachycardia, palpitations, elevation or decrease in blood pressure, hyperpnea, dyspnea or respiratory depression, dysuria, pollakiuria and even urinary retention, pruritus, morbilliform rash and sometimes edema. These disorders subside by decreasing the dose or suppressing the medication.

Overdose

Acute oral overdose can cause gastric irritation, especially nausea and vomiting, drowsiness, sedation, ataxia, insomnia, mental confusion, coma or tonic-clonic seizures, hepatotoxicity, jaundice, liver pain. These cases can be treated with gastric emptying and treatment for each particular case. In the presence of seizures, benzodiazepines should be used. In the presence of respiratory depression, tracheal intubation and mechanical ventilation assistance may be necessary. Central stimulant drugs should not be administered.

Interaction

Antiflu-Des capsules should not be administered concomitantly with monoamine oxidase inhibitors because they prolong and intensify the effect of antihistamines and severe hypotension may occur. Do not administer central nervous system depressants because the sedative effect of antihistamines can be enhanced. Metoclopramide can increase the intestinal absorption of paracetamol. Propantheline decreases the absorption of paracetamol. Ingestion of alcohol and antiepileptics may increase the hepatotoxicity of paracetamol. Associated amantadine with levodopa can cause psychotic reactions. Hallucinations and mental confusion may occur in patients with renal failure under antimuscarinic therapy.